Article
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.
All News
Article
A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.
Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.
Article
Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.
Article
The International Myositis Assessment and Clinical Studies Group (IMACS) have published evidence and consensus based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis.
Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.
Article
A matched cohort study from the Veterans Health Administration shows that rheumatoid arthritis patients have a >50% increased risk of lung cancer, and a 3-fold higher risk of lung cancer in RA-interstitial lung disease (ILD).
Eric Dein
Tweet
Give a listen to my @RheumNow interview w Josh Hsieh, a rising star at #ACR24, who is presenting his first (of many) research project as a high school sophomore!
His work w @NamrataRheum explores what is known- & not yet known- for cancer survival in RA
https://t.co/boqwpP9CUK https://t.co/UQ37pyvZT6
Eric Dein
Tweet
Ab#474 #ACR24
Hsieh and @NamrataRheum
Cancer Survival in RA
Unable to do meta-analysis due to lack of data
HR for lung cancer in RA 1.04
No clear evid of increased risk, but more data and studies needed
Great research project by a high school student (!!)
@RheumNow https://t.co/Sfrf2v2UO4
Eric Dein
Tweet
Risk for atypical femoral fracture:
🚨Asian race - 4-6x higher risk
Duration of use is greater risk than older age
Higher risk when given for osteoporosis than cancer treatment
- Compare: osteonecrosis of jaw more common with cancer Rx
#ACR24 Review Course
@RheumNow https://t.co/V8cD5QWNGp
Dr. John Cush
Tweet
Biosimilar Slow Growth in USA
A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and… https://t.co/yO3tUVk2jj https://t.co/ft6gqpnWMx
Dr. John Cush
Tweet
Cancer risk increased following, but not before, a systemic sclerosis diagnosis. From a dataset of 10.1 million individuals, 1588 Dx w/ SSc & 206 developed cancer. Most common mucocutaneous (4.5%), lung (2%) breast (2%). Cancer risk higher after the Dx of SSc (HR ~1.4)… https://t.co/9GNMOU28TQ https://t.co/czLEsXymIv
Dr. John Cush
Tweet
Cancer presenting as Inflammatory low back pain? 34 Cases presenting as SpA over 10 yrs often w/ higher ESR/CRP/LDH levels. CA included myeloma, leukemia, lymphoma, CA of breast/lung/prostate & bone tumors. https://t.co/YYKYx39tbD https://t.co/m9uCbJBsnU
Dr. John Cush
Tweet
CA-125 & PET/CT screening in 1432 myositis. 125 pts had CA-125 w/in 5yrs of onset - 3.1% false-positives (fibroids, endometriosis) & 14.3% false-negatives. 139 had PET done- 5.5% false-positives (LN, lung nodules), 28.6% false-negatives (missed melanoma, breast or prostate CA)… https://t.co/16KSDmp9Kz https://t.co/6QFl4jhDxp
Dr. John Cush
Tweet
Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi https://t.co/PtxRsTifi1
Dr. John Cush
Tweet
Points to Consider when Managing Inflammatory Arthritis with Cancer
https://t.co/qLMPwDNMiy https://t.co/sL87mp0gd4
Dr. John Cush
Tweet
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease
A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD.
https://t.co/J9FCdkId8H https://t.co/uJylDP3IIp
Dr. John Cush
Tweet
Breast CA (BC) & TNFi - study of 2 cohorts (Optum commercial * SEER/Medicare) found that 17% & 16% of BC pts received TNFi. 1 yr overall survival was no different +/- TNFi (HR= 0.77 & 0.84); but BC survival better on TNFi (HR 0.28; 0.08–0.98) vs csDMARDs. https://t.co/cGqT80rGTR https://t.co/n7i5VNFkVT
